DSM appoints new Executive Vice President Corporate Strategy & Acquisitions
Royal DSM announces the following:
Philip Eykerman, (1968), currently Partner at McKinsey & Company, Brussels office, will join DSM as Executive Vice President Corporate Strategy & Acquisitions, reporting to Feike Sijbesma, CEO and Chairman of the Managing Board of DSM.
Philip will succeed Hein Schreuder, currently EVP Corporate Strategy & Acquisitions, who after a very successful career of 20 years at DSM, will retire from the company on December 31, 2011. Hein has played a key role in the transformation of DSM as well as in the acquisitions and divestments of the company during the last 15 years.
Philip, a Belgian national, joined McKinsey & Company in 1997 and is the leader of McKinsey's Chemicals Practice in the Benelux and France. He has been heavily involved in a number of significant strategy development, transformation and M & A projects in the broader chemicals industry.
With his track record of strategy development and M & A strategy and integration, Philip is well positioned to lead DSM's corporate strategy and acquisition department and drive the development of DSM's strategic growth agenda.
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
VASTox plc announces positive preclinical results in its lead Duchenne Muscular Dystrophy programme
Affimed and Dyax Cross-License Antibody Technologies
Quintiles Opens Expanded Asia-Pacific Headquarters in Singapore
Clinical Trial Moves Stem Cell Therapy for ALS Patients One Step Closer to Reality
US Patents Granted for ARIUS Antibodies
S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
Chemokine Therapeutics Announces Change in Management
Probiodrug Announces Supervisory Board Changes - Appointment of Claus Braestrup as Chairman of the Supervisory Board
